Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.

Tzu-Lan Huang Fei-Yuan HsiaoChih-Kang ChiangLi-Jiuan ShenChih-Fen Huang

Published in: PloS one (2019)

DPP-4i were found to be associated with decreased risk of MACE in the non-CKD cohort in our study. However, DPP-4i were associated with increased risk of hHF in the CKD cohort. DPP-4i in the CKD cohort should be used cautiously.

Keyphrases

chronic kidney disease
cardiovascular events
end stage renal disease
coronary artery disease
cardiovascular disease
type diabetes